Polymer Free Everolimus
Eluting Coronary Stent System
World's 1st Polymer Free Everolimus Eluting Stent
ISAR Summit is a Summit of Innovative Technology that shall redefine the performance of drug-eluting stents as it contains Probucol which is a highly lipophilic drug and it retards the release of the drug thus ensuring proper endothelization, Microporous surface acts as a reservoir for delivering a drug to the targeted site and Everolimus which is a well-studied drug with higher bioavailability in target tissues.
Summit Of Innovative Technology
Summit Of Delivery Systems
Probucol - For Optimal Drug Release
*This is an example from the device with similar coat/matrix and similar drug
- Probucol obviates the Polymer related side effects of Acute Thrombogenicity, Inflammation, Delayed arterial healing.
- Due to its high lipophilicity it facilitates controlled release of Everolimus in similar manner to that achieved by polymers.
- Probucol and Everolimus co-release upto 80% in 28 days.*
- Probucol is a well studied drug at a much higher does (upto 500 mg) oral dosage with proven safety.
Technical Specifications
ISAR SUMMIT Technical Specifications
Ordering Information
Compliance Chart
